The FDA approval of Zarxio (filgrastim-sndz, Sandoz) and its most recent approval of Celltrion and Pfizer’s Inflectra (infliximab-dyyb) are just the harbingers of a looming market surge in biosimilars over the next decade. It’s a wave that is expected to lower health systems’ costs of expensive protein-based therapies by 15% to 20% initially—and perhaps much more, as additional competitors crowd into the field. However, the rate of speed to the U.S. market is likely to